Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

被引：0
|
作者：
Makharadze, T. [1 ]
Gogishvili, M. [2 ]
Melkadze, T. [3 ]
Baramidze, A. [3 ]
Giorgadze, D. [4 ]
Penkov, K. D. [5 ]
Laktionov, K. [6 ]
Nemsadze, G. [7 ]
Nechaeva, M. [8 ]
Rozhkova, I. [9 ]
Kalinka, E. [10 ]
Li, S. [11 ]
Li, Y. [11 ]
Kaul, M. [11 ]
Pouliot, J-F. [11 ]
Seebach, F. [11 ]
Lowy, I. [11 ]
Gullo, G. [11 ]
Rietschel, P. [11 ]
机构：
[1] High Technol Hosp Medctr, Batumi, Georgia
[2] High Technol Med Ctr, Tbilisi, Georgia
[3] Acad F Todua Med Ctr, Tbilisi, Georgia
[4] David Tvildiani Med Univ, Tbilisi, Georgia
[5] Private Med Inst Euromedserv, St Petersburg, Russia
[6] Minist Hlth Russian Federat, Fed State Budgetary Inst, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia
[7] Inst Clin Oncol, Tbilisi, Georgia
[8] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia
[9] Kaluga Reg Clin Oncol Dispensary, Kaluga, Russia
[10] Polish Mothers Mem Hosp Res Inst, Lodz, Poland
[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5O
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
    Zhang, Mengdie
    Xu, Kai
    Lin, Yingtao
    Zhou, Chongchong
    Bao, Yuwen
    Zhang, Lingli
    Li, Xin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial
    Makharadze, T.
    Quek, R. G.
    Melkadze, T.
    Gogishvili, M.
    Ivanescu, C.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Konidaris, G.
    Rietschel, P.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1414 - S1414
  • [43] Induction chemotherapy versus chemoradiotherapy for stage III non-small cell lung cancer
    Higgins, K. A.
    Clough, R.
    Marks, L.
    Kelsey, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S59 - S60
  • [44] Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI plus CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
    Gogishvili, M.
    Melkadze, T.
    Baramidze, A.
    Makharadze, T.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G. W.
    ANNALS OF ONCOLOGY, 2023, 34
  • [45] Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study
    Prabhash, Kumar
    Babu, Kanaka Govind
    Vaid, Ashok K.
    Rangaraju, Ranga Rao
    Sirohi, Bhawna
    Diwakar, Ravi
    Rao, Raghunadha
    Kar, Madhuchanda
    Malhotra, Hemant
    Nag, Shona Milon
    Goswami, Chanchal
    Raina, Vinod
    Mohan, Pedapenki Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Cisplatin plus vinorelbine chemotherapy for non-small cell lung cancer
    Pereira, JR
    Gampel, O
    Martins, SJ
    Ikari, FK
    Nikaedo, SM
    Paschoalini, M
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 643 - 646
  • [47] Kanglaite Injection Plus Chemotherapy Versus Chemotherapy Alone for Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
    Liu, Xuemei
    Xu, Feng
    Wang, Gang
    Diao, Xiang
    Li, Youping
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2008, 69 (05): : 381 - 411
  • [48] Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
    Jian, Hong
    Li, Wei
    Ma, Zhiyong
    Huang, Jianjin
    Feng, Jifeng
    Song, Yong
    Gao, Beili
    Zhu, Huili
    Tao, Min
    Bai, Chong
    Ma, Shenglin
    Pan, Hongming
    Qin, Shukui
    Hua, Dong
    Yu, Yongfeng
    Lu, Shun
    SCIENTIFIC REPORTS, 2017, 7
  • [49] Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
    Hong Jian
    Wei Li
    Zhiyong Ma
    Jianjin Huang
    Jifeng Feng
    Yong Song
    Beili Gao
    Huili Zhu
    Min Tao
    Chong Bai
    Shenglin Ma
    Hongming Pan
    Shukui Qin
    Dong Hua
    Yongfeng Yu
    Shun Lu
    Scientific Reports, 7
  • [50] COST-EFFECTIVENESS OF CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY AS THE FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER: A PRELIMINARY STUDY
    Xue, X.
    Ngorsuraches, S.
    Qian, J.
    VALUE IN HEALTH, 2024, 27 (06) : S353 - S353
12345